check quantity

Amyloid β 1-15 (human) AlphaLISA Detection Kit, 5,000 Assay Points

The AlphaLISA® Human Amyloid beta 1-15 (Aß 1-15) Detection Kit is designed for detection and quantitation of human Aß 1-15 in cerebrospinal fluid (CSF), buffered solution or cell culture medium in a homogeneous (no-wash steps, no separation steps) assay.

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Product Number Unit Size List Price Your Price Quantity
AL274C 500 assay points 2745.00 USD
AL274F 5,000 assay points 21500.00 USD

You successfully added item(s) to your cart

Overview

One antibody is specific to the ß-secretase cleavage site at the N-terminus: mouse monoclonal antibody, clone number 82E1. The second antibody is mouse monoclonal antibody, clone number 2B3 that is specific to the C-terminus of Aß 1-15.

Formats:

  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

Amyloid beta (Aß) is a short peptide derived from the proteolysis of a larger transmembrane molecule, the amyloid precursor protein (APP). The cleavage of Aß from APP is carried out by several proteolytic enzymes termed a-, ß- and ?-secretases. In the amyloidogenic pathway, APP is cleaved by ß-secretase and the remaining fragment is cleaved by ?-secretase, generating Aß 1-40, Aß 1-42 and other minor forms. In the non-amyloidogenic pathway, a-secretase cleaves APP in the middle of the Aß sequence, to produce secreted APPa and an internalized C-terminal fragment, precluding Aß formation. In a third pathway, APP is cleaved by ß-secretase followed by a-secretase, resulting in the release of several short Aß isoforms (Aß 1-16 down to Aß 1-13). The increased Aß 1-16 reported in cerebrospinal fluid from patients with Alzheimer's disease (AD), might result from an upregulation of this pathway as an attempt to counteract amyloidogenic APP processing. Therefore, Aß 1-16 is a novel biomarker for AD.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Disclaimer: For research use only. Not for use in diagnostic procedures.

Specifications

Assay Target Aβ1-15
Assay Target Class Peptide
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Central Nervous System
Unit Size 5,000 assay points

Resources, Events & More

Resource Type File Name File Format
Technical Note HiBlock Buffer Technical Data Sheet PDF 333 KB
Data Sheet Manual AlphaLISA Human Aß 1-15 AL274 PDF 210 KB
Poster AlphaLISA Assays are Homogeneous Sensitive Immunoassays for Detection of Analytesin a Variety of Biological Matrices PDF 273 KB